Anti-breast cancer activity of fine black ginseng (Panax ginseng Meyer) and ginsenoside Rg5

Journal of Ginseng Research

Volumn 39, Issue 2, 2015, Pages 125-134

  Kim, Shin Jung ^a   Kim, An Keun ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Anticancer; Breast cancer; Cell cycle arrest; Fine black ginseng (Panax ginseng Meyer); Ginsenoside Rg5

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN E; CYCLIN E2; CYTOCHROME C; FINE BLACK GINSENG EXTRACT; GINSENG EXTRACT; GINSENOSIDE; GINSENOSIDE F1; GINSENOSIDE F4; GINSENOSIDE RB 1; GINSENOSIDE RB 2; GINSENOSIDE RC; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RG 1; GINSENOSIDE RG 2; GINSENOSIDE RG 3; GINSENOSIDE RG 6; GINSENOSIDE RG5; GINSENOSIDE RH 1; GINSENOSIDE RH 2; GINSENOSIDE RH 4; GINSENOSIDE RK 1; GINSENOSIDE RK 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL CYCLE ASSAY; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG MECHANISM; G1 PHASE CELL CYCLE CHECKPOINT; GINSENG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MCF 7 CELL LINE; MTT ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; WESTERN BLOTTING;

PANAX GINSENG;

EID: 84926204854     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgr.2014.09.003     Document Type: Article

References (43)

1. Namba T. The encyclopedia of Wakan-Yaku with color pictures. Osaka: Hoikusha; 1980.
2. Park JD. Recent studies on the chemical constituents of Korean Ginseng (Panax ginseng C.A. Meyer). Korea J Ginseng Sci 1996;20:389-415.
3. Yokozawa T, Kobayashi T, Oura H, Kawashima Y. Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb2 in streptozotocin-diabetic rats. Chem Pharm Bull (Tokyo) 1985;33:869-72.
4. Park SE, Park C, Kim SH, Hossain MA, Kim MY, Chung HY, Son WS, Kim GY, Choi YH, Kim ND. Korean Red Ginseng extract induces apoptosis and decreases telomerase activity in human leukemia cells. J Ethnopharmacol 2009;121:304-12.
5. Fukushima S, WanibuchiH LW. Inhibition by ginseng of colon carcinogenesis in rats. J Korean Med Sci 2001;16:75-80.
6. Keum YS, Han SS, Chun KS, Park KK, Park JH, Lee SK, Surh YJ. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion. Mutat Res 2003;523-524:75-85.
7. Kim ND, Kang SY, Park JH, Schini-Kerth VB. Ginsenoside Rg3 mediates endothelium-dependent relaxation in response to ginsenosides in rat aorta: role of Kþ channels. Eur J Pharmacol 1999;367:41-9.
8. Keum YS, Park KK, Lee JM, Chun KS, Park JH, Lee SK, Kwon H, Surh YJ. Antioxidant and anti-tumor promoting activities of the methanol extract of heatprocessed ginseng. Cancer Lett 2000;150:41-8.
9. Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 2004;9:259-74.
10. Oh M, Choi YH, Choi S, Chung H, Kim K, Kim SI, Kim DK, Kim ND. Antiproliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol 1999;14:869-75.
11. Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS, Du W. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 2011;301:185-92.
12. Choi S, Kim TW, Singh SV. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1dependent inhibition of cyclin-dependent kinases. Pharm Res 2009;26: 2280-8.
13. Lee SA, Jo HK, Im BO, Kim S, Whang WK, Ko SK. Changes in the contents of prosapogenin in the Red Ginseng (Panax ginseng) depending on steaming batches. J Ginseng Res 2012;36:102-6.
14. Lee YY, Park JS, Jung JS, Kim DH, Kim HS. Anti-inflammatory effect of ginsenoside Rg5 in lipopolysaccharide-stimulated BV2 microglial cells. Int J Mol Sci 2013;14:9820-33.
15. Kim EJ, Jung IH, Van Le TK, Jeong JJ, Kim NJ, Kim DH. Ginsenosides Rg5 and Rh3 protect scopolamine-induced memory deficits in mice. J Ethnopharmacol 2013;146:294-9.
16. Shin YW, Bae EA, Kim DH. Inhibitory effect of ginsenoside Rg5 and its metabolite ginsenoside Rh3 in an oxazolone-induced mouse chronic dermatitis model. Arch Pharm Res 2006;29:685-90.
17. Lee KY, Lee YH, Kim SI, Park JH, Lee SK. Ginsenoside-Rg5 suppresses cyclin E dependent protein kinase activity via up-regulating p21Cip/WAF1 and downregulating cyclin E in SK-HEP-1 cells. Anticancer Res 1997;17:1067-72.
18. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64: 9-29.
19. Statistics Korea. 2012 Annual report on the cause of death statistics. In: Office KNS, editor. Daejeon, Korea: Statistics Korea; 2013.
20. Lee JH, Shen GN, Kim EK, Shin HJ, Myung CS, Oh HJ, Kim DH, Roh SS, Cho W, Seo YB, et al. Preparation of black ginseng and its antitumor activity. Korean J Oriental Physiol Pathol 2006;20:951-6.
21. Ko SK, Bae HM, Cho OS, Im BO, Chung SH, Lee BY. Analysis of ginsenoside composition of ginseng berry and seed. Food Sci Biotechnol 2008;17: 1379-82.
22. Kim SI, Park JH, Ryu JH, Park JD, Lee YH, Kim TH, Baek NI. Ginsenoside Rg5, a genuine dammarane glycoside from Korean red ginseng. Arch Pharm Res 1996;19:551-3.
23. Han ST, Whang WK, Kim IH, Yang BW, Cho SH, Ko SK. Analysis of ginsenosides of Black Ginseng. Yakhak Hoeji 2005;49:490-4.
24. Benhar M, Dalyot I, Engelberg D, Levitzki A. Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 2001;21:6913-26.
25. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006;5:1087-98.
26. Jo HK, Sung MC, Ko SK. The comparison of ginseng prosapogenin composition and contents in Red and Black ginseng. Kor J Pharmacogn 2011;42:361-5.
27. Kang KS, Kim HY, Yamabe N, Yokozawa T. Stereospecificity in hydroxyl radical scavenging activities of four ginsenosides produced by heat processing. Bioorg Med Chem Lett 2006;16:5028-31.
28. Choi YJ, Lee HJ, Kang DW, Han IH, Choi BK, Cho WH. Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species. Oncol Rep 2013;30: 1362-70.
29. Song Y, Hou J, Kang L, Gao S. Effect of 20(S)-ginsenoside Rg3 on the proliferation inhibition and secretion of vascular endothelial growth factor of multiple myeloma cell line U266 [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 2014;35:519-23.
30. Kim JW, Jung SY, Kwon YH, Lee JH, Lee YM, Lee BY, Kwon SM. Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. Cancer Biol Ther 2012;13:504-15.
31. Park HM, Kim SJ, Kim JS, Kang HS. Reactive oxygen species mediated ginsenoside Rg3- and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways. Food Chem Toxicol 2012;50:2736-41.
32. Pan XY, Guo H, Han J, Hao F, An Y, Xu Y, Xiaokaiti Y, Pan Y, Li XJ. Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC3M prostate cancer cells. Eur J Pharmacol 2012;683:27-34.
33. Yu Y, Zhang C, Liu L, Li X. Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas. Exp Ther Med 2013;5:761-6.
34. Guo XX, Li Y, Sun C, Jiang D, Lin YJ, Jin FX, Lee SK, Jin YH. p53-dependent Fas expression is critical for Ginsenoside Rh2 triggered caspase-8 activation in HeLa cells. Protein Cell 2014;5:224-34.
35. Sheu MJ, Chou PY, Huang CS, Tsai IC, Chien YC, Lin SY, Tsai HY, Cheng HC, Wu CH. Pipoxolan inhibits proliferation of HL-60 human leukaemia cancer cells by arresting the cell cycle at the G0/G1 phase. Clin Exp Pharmacol Physiol 2010;37:605-12.
36. Morrison RS, Wenzel HJ, Kinoshita Y, Robbins CA, Donehower LA, Schwartzkroin PA. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J Neurosci 1996;16:1337-45.
37. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ 2006;13:951-61.
38. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003;15:164-71.
39. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
40. Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003;63:2369-72.
41. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998;1366(1-2):177-96.
42. Shang XJ, Yao G, Ge JP, Sun Y, Teng WH, Huang YF. Procyanidin induces apoptosis and necrosis of prostate cancer cell line PC-3 in a mitochondriondependent manner. J Androl 2009;30:122-6.
43. Nam KY, Choi JE, Park JD. Transformation Techniques for the Large Scale Production of Ginsenoside Rg3. Korean J Medicinal Crop Sci 2013;21(5):401-14.